We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Smiths Group Plc | LSE:SMIN | London | Ordinary Share | GB00B1WY2338 | ORD 37.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -27.00 | -1.65% | 1,608.00 | 1,611.00 | 1,612.00 | 1,640.00 | 1,609.00 | 1,639.00 | 595,498 | 16:35:16 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Srch,det,nav,guid,aero Sys | 3.04B | 231M | 0.6613 | 24.35 | 5.62B |
From Apr 2019 to Apr 2024
By Euan Conley
Smiths Group PLC (SMIN.LN) confirmed that it has entered talks with ICU Medical Inc. (ICUI) over a potential merger of both companies' healthcare operations.
The U.K. engineering company said in a statement Sunday that it was in the "very early" stage of discussions over a potential combination with U.S.-based ICU Medical.
"The board of Smiths routinely reviews all options for the Group's portfolio of businesses to maximise value for Smiths shareholders," the company said in a statement.
Smiths group, which has a market cap of 6.81 billion pounds ($9.05 billion), added that there was no certainty that the merger will be concluded.
ICU Medical manufactures medical devices used in oncology, vascular therapy and critical care. The company struck an agreement in 2016 to buy Pfizer Inc.'s(PFE) Hospira infusion-systems business in a $1 billion cash-and-stock deal.
Write to Euan Conley at euan.conley@dowjones.com
(END) Dow Jones Newswires
May 28, 2018 05:16 ET (09:16 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Smiths Chart |
1 Month Smiths Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
